title: The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer.
abstract: The role of targeted therapies in the treatment of women with breast cancer has been rapidly evolving. Trastuzumab, a monoclonal antibody against the human epidermal growth factor receptor 2 (HER2), was the first HER2-targeted therapy that clearly demonstrated a significant clinical benefit for women with HER2-overexpressing metastatic breast cancer (mbc). However, in recent years it has become increasingly apparent that, when trastuzumab is used in the first-line setting in combination with chemotherapy, most women eventually develop progressive disease. Determining the treatment options available to women who have progressed while on trastuzumab therapy has been hampered by a paucity of high-quality published data. In addition, with the standard use of trastuzumab in the adjuvant setting (for eligible HER2-positive patients), the role of anti-HER2 agents for patients who experience a breast cancer relapse has become a clinically relevant question. This manuscript reviews current available data and outlines suggestions from a panel of Canadian oncologists about the use of trastuzumab and other HER2-targeted agents in two key mbc indications:Treatment for women with HER2-positive mbc progressing on trastuzumab (that is, treatment beyond progression)Treatment for women with HER2-positive mbc recurring following adjuvant trastuzumab (that is, re-treatment)The suggestions set out here will continue to evolve as data and future trials with trastuzumab and other HER2-targeted agents emerge.
authors: The Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, ON. sdent@ottawahospital.on.ca
authors: S
authors: S
authors: Dent
authors: Sh
authors: Sh
authors: Verma
authors: J
authors: J
authors: Latreille
authors: D
authors: D
authors: Rayson
authors: M
authors: M
authors: Clemons
authors: J
authors: J
authors: Mackey
authors: Su
authors: S
authors: Verma
authors: J
authors: J
authors: Lemieux
authors: L
authors: L
authors: Provencher
authors: S
authors: S
authors: Chia
authors: B
authors: B
authors: Wang
authors: K
authors: K
authors: Pritchard